ArcherDX Acquired By Enzymatics

Boulder-based ArcherDX, which develops testing and diagnostics kits for cancer, has been acquired by Enzymatics, a developer of reagents, kits, and assays for the life sciences market. Financial details of the acquisition, which was announced late last week, were not announced. Enzymatics said that Jason Myers, the co-founder and CEO of ArcherDX, has become its Chief Scientific Officer. Myers had previously been at Life Technologies before starting Enzymatics.